#1 Clinical Trials Search in Europe

Tavapadon

Tavapadon is an investigational drug being studied as a potential treatment for Parkinson’s disease. Several clinical trials are currently underway to evaluate its safety, efficacy, and optimal dosing in patients with early-stage and advanced Parkinson’s disease. These trials aim to determine if tavapadon can improve motor symptoms, reduce “off” time, and enhance quality of life for people living with this progressive neurological condition.

Table of Contents

What is Tavapadon?

Tavapadon, also known as PF-06649751 or CVL-751, is a new medication being developed to treat Parkinson’s disease (PD)[1]. Parkinson’s disease is a progressive neurological disorder that affects movement, causing symptoms like tremors, stiffness, and difficulty with balance and coordination. Tavapadon is currently undergoing clinical trials to evaluate its effectiveness and safety in treating both early-stage Parkinson’s disease and more advanced stages where patients experience motor fluctuations[2].

How Tavapadon Works

While the exact mechanism of action is not fully described in the provided clinical trial information, Tavapadon is likely designed to target the dopamine system in the brain. Parkinson’s disease is characterized by a loss of dopamine-producing cells, and many treatments aim to replace or mimic the effects of dopamine. Tavapadon is being tested as both a standalone treatment for early Parkinson’s disease and as an adjunctive (add-on) therapy for patients already taking levodopa, a common Parkinson’s medication[2][1].

Clinical Trials of Tavapadon

Several clinical trials are currently underway to evaluate Tavapadon:

  • TEMPO-1 Trial: This is a Phase 3 trial testing two fixed doses (5 mg and 15 mg) of Tavapadon in patients with early Parkinson’s disease[3].
  • TEMPO-2 Trial: Another Phase 3 trial using flexible doses of Tavapadon (up to 15 mg) in early Parkinson’s disease[1].
  • TEMPO-3 Trial: This Phase 3 trial is testing Tavapadon as an add-on therapy for patients with more advanced Parkinson’s disease who are experiencing motor fluctuations while on levodopa treatment[2].
  • TEMPO-4 Trial: An open-label trial to evaluate the long-term safety and efficacy of Tavapadon over 58 weeks[4].

These trials are designed to assess how well Tavapadon improves motor symptoms of Parkinson’s disease, its safety profile, and its effects on quality of life for patients.

Potential Benefits of Tavapadon

Based on the clinical trials, researchers are investigating several potential benefits of Tavapadon:

  • Improved motor function: The trials are measuring changes in the Movement Disorder Society – Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), which assesses motor symptoms and daily living activities[1].
  • Reduced “off” time: For patients with motor fluctuations, Tavapadon may help increase “on” time (when symptoms are well-controlled) and reduce “off” time (when symptoms return)[2].
  • Flexible dosing: Some trials are exploring flexible dosing options, which could allow for personalized treatment[1].
  • Long-term effectiveness: The TEMPO-4 trial is investigating the long-term effects of Tavapadon over more than a year[4].

Possible Side Effects and Safety Considerations

As with any new medication, researchers are carefully monitoring for potential side effects and safety issues. The clinical trials are assessing:

  • Treatment-emergent adverse events (TEAEs): These are any new medical problems or worsening of existing conditions that occur during treatment[1].
  • Sleepiness: Using the Epworth Sleepiness Scale to measure daytime drowsiness[1].
  • Impulsive behaviors: Monitoring for any development of impulse control disorders using the Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS)[4].
  • Suicidal thoughts: Assessing any changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale (C-SSRS)[1].
  • Withdrawal symptoms: Evaluating any potential withdrawal effects when stopping the medication[4].

It’s important to note that the full safety profile of Tavapadon will only be known after the completion of these clinical trials and review by regulatory authorities.

Ongoing Research and Future Prospects

In addition to the main clinical trials, researchers are conducting studies to understand how Tavapadon interacts with other medications and how it’s processed by the body:

  • A study on how Tavapadon is affected by carbamazepine, a medication that can influence drug metabolism[5].
  • Investigations into how Tavapadon is processed in people with kidney or liver impairment[6][7].
  • A detailed study on how Tavapadon is absorbed, metabolized, and eliminated from the body[8].

These additional studies will help doctors understand how to best use Tavapadon in different patient populations and alongside other medications.

While Tavapadon shows promise, it’s important to remember that it is still an experimental drug. If the clinical trials are successful, it will need to be reviewed and approved by regulatory agencies before becoming available to patients. The ongoing research aims to provide a new treatment option that could improve the lives of people living with Parkinson’s disease.

Aspect Details
Drug Name Tavapadon (also known as PF-06649751, CVL-751)
Condition Studied Parkinson’s Disease (early-stage and advanced)
Trial Phases Phase 1 and Phase 3
Dosing Oral tablets, typically 5-15 mg once daily
Trial Duration Ranging from 27 to 58 weeks
Primary Outcomes Changes in MDS-UPDRS scores, “on” time without troublesome dyskinesia
Secondary Outcomes Quality of life measures, safety assessments, pharmacokinetics
Safety Monitoring Adverse events, vital signs, lab values, ECG, suicidality assessment
Special Populations Studies in patients with renal and hepatic impairment

Ongoing Clinical Trials on Tavapadon

  • Study on the Long-Term Safety of Tavapadon for Patients with Parkinson’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Italy +2

Glossary

  • Parkinson's Disease (PD): A progressive neurological disorder that affects movement, often including tremors, stiffness, and difficulty with walking, balance, and coordination.
  • MDS-UPDRS: The Movement Disorder Society-Unified Parkinson's Disease Rating Scale, a comprehensive assessment tool used to measure the severity of Parkinson's disease symptoms.
  • Motor fluctuations: Changes in the ability to move that occur in Parkinson's disease patients, often as a complication of long-term levodopa therapy.
  • On time: Periods when Parkinson's medications are working well and symptoms are under control.
  • Off time: Periods when Parkinson's medications are not working well and symptoms return.
  • Dyskinesia: Involuntary, erratic writhing movements that can occur as a side effect of long-term Parkinson's disease treatment.
  • Levodopa: A medication commonly used to treat Parkinson's disease symptoms.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Bioequivalence: A term used to describe when two medications have the same active ingredient and produce the same effect in the body.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Columbia-Suicide Severity Rating Scale (C-SSRS): A questionnaire used to assess suicide risk in clinical trials and other settings.

References

  1. https://clinicaltrials.gov/study/NCT04223193
  2. https://clinicaltrials.gov/study/NCT04542499
  3. https://clinicaltrials.gov/study/NCT04201093
  4. https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-tavapadon-for-patients-with-parkinsons-disease/
  5. https://clinicaltrials.gov/study/NCT05581823
  6. https://clinicaltrials.gov/study/NCT05404542
  7. https://clinicaltrials.gov/study/NCT05404529
  8. https://clinicaltrials.gov/study/NCT04241393